Bruce R. Troen, MD, professor of medicine and chief of the Division of Geriatrics and Palliative Medicine, is cautioning against “unequivocal enthusiasm” for aducanumab, a new drug approved by the Food and Drug Administration to fight Alzheimer’s disease.